CD274 and triple-negative breast carcinoma: In the former, atezolizumab and nab-paclitaxel are combined, and it is shown that this prolongs progression-free survival in patients with metastatic triple-negative breast cancer who have intention-to-treat as well as in the subgroup of patients who have PD-L1 positive.